# UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference
Ticker: URGN
Company: UroGen Pharma
Source: UroGen Pharma
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.urogen.com
## Summary

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47 th Annual Global Healthcare Conference to

## Article Body
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47 th Annual Global Healthcare Conference to
## Recent Company News
- 2026-06-25 13:46 EST — [UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution](https://biopharmsignal.com/news/URGN/urogen-announces-agreement-resolving-patent-litigation-relating-to-jelmytor-mitomycin-for-pyelocalyceal-solution) — Source: UroGen Pharma
- 2026-06-25 13:46 EST — [UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: UroGen Pharma
- 2026-06-25 13:46 EST — [UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC](https://biopharmsignal.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc) — Source: UroGen Pharma
- 2026-06-25 13:46 EST — [ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial](https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial) — Source: UroGen Pharma
- 2026-06-25 13:46 EST — [UroGen Pharma to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences) — Source: UroGen Pharma
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)